Primary pulmonary plasmacytoma: A case report.

Rationale: Extramedullary plasmacytoma is an extremely rare malignant clonal plasmacytoma, which can occur in any tissue or organ of the body other than bone marrow hematopoietic tissue. Lesions mostly occur in the head and neck or upper respiratory tract, and rarely in the lower respiratory tract. Primary plasmacytoma of the lung, also known as primary pulmonary plasmacytoma (PPP), is rarer and is mainly diagnosed on the basis of the histopathology of biopsy tissue.

Role of Imaging in Multiple Myeloma: A Potential Opportunity for Quantitative Imaging and Radiomics?

Multiple myeloma (MM) is the second most prevalent hematologic malignancy, particularly affecting the elderly. The disease often begins with a premalignant phase known as monoclonal gammopathy of undetermined significance (MGUS), solitary plasmacytoma (SP) and smoldering multiple myeloma (SMM). Multiple imaging modalities are employed throughout the disease continuum to assess bone lesions, prevent complications, detect intra- and extramedullary disease, and evaluate the risk of neurological complications.

Extra-medullary Plasmacytomas: A Case Series of Rare Hematological Tumors.

Solitary plasmacytoma is a rare malignant tumor belonging to the family of plasma cell proliferation. It accounts for a small portion of plasma cell tumors and remains a rare condition. We report three cases of rare extraosseous plasmacytomas in young patients.

Extramedullary plasmacytoma of the pancreas diagnosed by endoscopic ultrasonography-guided fine needle biopsy.

EMP in the head of the pancreas is difficult to diagnose, many of them postmortem, EUS-FNB in experienced hands in conjunction with immunohistochemistry and flow cytometry is a valuable tool.

Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma.

Multiple myeloma (MM) remains incurable, with poor outcomes in heavily pre-treated patients with plasmacytomas. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment option; however, outcomes after such therapy in patients with soft-tissue plasmacytomas and other bone lesions remain poorly understood. Data regarding these parameters is scarce within the specific context of CAR T-cell treatment.

Outcome Analysis of Solitary Extramedullary Plasmacytoma in the Head and Neck: A Clinical Perspective.

Introduction: Solitary extramedullary plasmacytomas (SEP) of the head and neck are rare and pose unique challenges. This study aimed to explore the clinical spectrum and treatment outcomes of these neoplasms using multimodal management.

Methods: A retrospective review of 13 patients with SEP of the head and neck.

Efficacy of Daratumumab-Based Regimens for Extramedullary Pulmonary Plasmacytoma: A Case Report.

Introduction: Multiple myeloma (MM) with pulmonary extramedullary disease is rare and usually associated with poor prognosis, and no data on daratumumab-based regimens have been reported yet.

Case Presentation: Here, a 64-year-old man with pulmonary plasmacytoma received daratumumab-based regimens and has achieved a very good partial response with lung mass disappearance and overall survival of 16 months. He did not receive autologous stem cell transplantation because of several comorbidities, such as severe drug-induced neuropathy and JAK2-mutated myeloproliferative neoplasm with marked splenomegaly.

Bilateral Breast Involvement in Multiple Myeloma: A Report of a Rare Case.

Breast plasmacytoma is an uncommon extramedullary manifestation of multiple myeloma (MM). This case presents a primary extramedullary plasmacytoma and progression to MM with breast involvement after 12 years of discovering the disease. The patient is a 54-year-old woman who initially presented with a right humerus pathological fracture that turned out to be a primary extramedullary plasmacytoma.

Adding Evidence to Plasmacytoma: A Case Series.

Plasmacytoma is a rare tumor of plasma cells with two primary variants: solitary bone plasmacytoma (SBP) and extramedullary plasmacytoma (EMP). It poses diagnostic challenges at times. Radiotherapy (RT) is the curative modality in the majority of cases.